Positives

• After at least two PT-141 sessions, 80% of male participants reported being more satisfied with their lovemaking experience and its duration World Journal of Men's Health.
  
  
• Premenopausal women treated with bremelanotide for hypoactive sexual desire disorder reported more spontaneous sexual thoughts and a greater willingness to initiate sex compared with placebo PMC.
  
  

Negatives

• Up to 40% of patients experienced nausea after dosing, with about 20% reporting facial flushing and 12% reporting headaches PMC.
  
  
• A patient described flushing intense enough that they had to sit in front of a fan with a cold rag while waiting for the effect to subside Drugs.com.
  
  

Hurdles & Side Effects

• Bremelanotide is FDA-approved only for HSDD in premenopausal women, so post-COVID patients with autonomic or libido issues face entirely off-label prescribing Mayo Clinic.
  
  
• A patient sensitive to autonomic surges had to time PT-141 carefully because the same melanocortin activation that drives benefit can transiently raise blood pressure Long-Term Safety Study.